Sign up to save your podcasts
Or
Share New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition
Awareness, Advances, Action: Optimizing Outcomes for Patients with Generalized Myasthenia Gravis
In the first half of this two-part episode, Dr. Kelly Gwathmey, MD, and Dr. Pushpa Narayanaswami, MD, FAAN, first discuss the evolving landscape of generalized myasthenia gravis (gMG) treatment, including the foundational role of conventional immunotherapies and the emergence of novel agents like FcRn receptor antagonists and complement inhibitors. Learn about the mechanisms, clinical trial data, and practical considerations for integrating these therapies into patient care.
To access the other episodes in the gMG disease dialogues series and earn CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/advances-gmg-disease-dialogues-series/. The series features expert discussion on the new and emerging therapies for gMG, practical insights for integrating treatment advances, and the importance of multidisciplinary collaboration to optimize patient care.
Earn free CME credits- visit https://myastheniagravis.ime.springerhealthcare.com/ to check out the complete accredited program on optimizing patient outcomes in gMG.
Intended for healthcare professionals only.
Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.
View all episodes
By Springer Health+ IMEAwareness, Advances, Action: Optimizing Outcomes for Patients with Generalized Myasthenia Gravis
In the first half of this two-part episode, Dr. Kelly Gwathmey, MD, and Dr. Pushpa Narayanaswami, MD, FAAN, first discuss the evolving landscape of generalized myasthenia gravis (gMG) treatment, including the foundational role of conventional immunotherapies and the emergence of novel agents like FcRn receptor antagonists and complement inhibitors. Learn about the mechanisms, clinical trial data, and practical considerations for integrating these therapies into patient care.
To access the other episodes in the gMG disease dialogues series and earn CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/advances-gmg-disease-dialogues-series/. The series features expert discussion on the new and emerging therapies for gMG, practical insights for integrating treatment advances, and the importance of multidisciplinary collaboration to optimize patient care.
Earn free CME credits- visit https://myastheniagravis.ime.springerhealthcare.com/ to check out the complete accredited program on optimizing patient outcomes in gMG.
Intended for healthcare professionals only.
Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.